Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

99.84 +1.00 (+1.02%)
Streaming Delayed Price Updated: 11:32 AM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
20 21 22 23 24 25 26 27 Next >
News headline image
Annual Changes To The Nasdaq-100 Index ↗
The reconstituted Nasdaq index for 2022 (effective Dec. 20, 2021) has six new members; they replace FOX, TCOM, INCY, CDW, CERN, and CHKP. 
Via Talk Markets
News headline image
Incyte Announces Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
From Incyte
Via Business Wire
News headline image
7 CEOs That Ought to Follow Jack Dorsey Out the Door ↗
Jack Dorsey stepped down as Twitter CEO despite stock gains, but not every CEO can say the same. Here are seven CEOs who need to go. 
Via InvestorPlace
News headline image
Expert Ratings For Incyte ↗
Over the past 3 months, 6 analysts have published their opinion on Incyte (NASDAQ: 
Via Benzinga
Drug Combinations and New Approvals Delivering Optimistic Results in Oncology Stocks
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 8, 2021 – USA News Group – Growing at a healthy CAGR of 14.1%, the Cancer Immunotherapy Market is being projected to hit... 
Via FinancialNewsMedia
News headline image
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
News headline image
7 Stocks 'On Sale' This Holiday Season ↗
This time of year, it may feel like you’ve missed out on big rallies in the best stocks. But, there may still be a chance to buy some high-quality stocks for 2022 at a discount to what you would have... 
Via Talk Markets
News headline image
7 Stocks 'On Sale' This Holiday Season ↗
The SPDR S&P 500 ETF Trust (NYSE: SPY) has generated a total return of 26.4% year-to-date, but much of those overall gains have been driven by a handful of megacap stocks. In... 
Via Benzinga
Topics Stocks
News headline image
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar? ↗
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation... 
Via Benzinga
News headline image
Stocks Most Impacted by 7-10 Year Treasuries ↗
A look at S&P 500 members that perform best when the iShares 7-10 Year Treasury Bonds ETF (IEF) loses value. 
Via Talk Markets
Topics Stocks
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 ↗
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
More than 35 Abstracts from Incyte’s Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition
From Incyte
Via Business Wire
News headline image
Incyte Corporation (INCY) Q3 2021 Earnings Call Transcript ↗
INCY earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
News headline image
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
News headline image
A Peek Into The Markets: US Stock Futures Edge Lower; Fed Meeting In Focus ↗
Pre-open movers U.S. stock futures traded slightly lower in early pre-market trade after settling at record highs in the previous session. The Federal Open Market Committee will... 
Via Benzinga
Topics Economy
News headline image
Incyte's Parsaclisib Application Under FDA Review For 3 Types Of Non-Hodgkin Lymphomas ↗
The FDA has accepted for review Incyte Corporation's (NASDAQ: INCY) marketing application for parsaclisib for relapsed or refractory follicular lymphoma (FL),... 
Via Benzinga
News headline image
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
From Incyte
Via Business Wire
News headline image
Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas
From Incyte
Via Business Wire
News headline image
Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo
From Incyte
Via Business Wire
News headline image
2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays ↗
It's much too early to count these companies out. 
Via The Motley Fool
News headline image
Could This Be the Next Blockbuster Indication for Eli Lilly? ↗
Eli Lilly and Incyte's Olumiant could be a groundbreaking therapy for patients with alopecia areata. 
Via The Motley Fool
News headline image
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
News headline image
Incyte to Report Third Quarter Financial Results
From Incyte
Via Business Wire
News headline image
Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
From Incyte
Via Business Wire
News headline image
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates ↗
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
News headline image
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... 
Via Benzinga
< Previous 1 2
...
20 21 22 23 24 25 26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.